证券代码：300497 证券简称：富祥药业 公告编号：2023-046 江西富祥药业股份有限公司 关于参加江西辖区上市公司2023年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，江西富祥药业股份有限公司（以下简称"公 司"）将参加由江西证监局、江西省上市公司协会与深圳市全景网络有限公司联合举 办的"2023年江西辖区上市公司投资者集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演APP，参与本 次互动交流，活动时间为2023年5月19日（周五）14:30—17:00。届时公司高管将在线 就公司2022年度业绩、公司治理、发展战略、经营情况、融资计划、股权激励和可持 续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 江西富祥药业股份有限公司 董事会 2023 年 5 月 15 日 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2022, representing a year-on-year increase of 15%[24]. - The gross profit margin improved to 45%, up from 42% in the previous year, indicating enhanced operational efficiency[24]. - The company achieved a net profit of RMB 300 million, reflecting a 10% increase compared to the previous year[24]. - The company's operating revenue for 2022 was ¥1,647,263,426.90, an increase of 15.23% compared to ¥1,429,542,874.53 in 2021[32]. - The net profit attributable to shareholders was a loss of ¥141,471,326.16 in 2022, a decrease of 389.72% from a profit of ¥48,830,662.43 in 2021[32]. - The net cash flow from operating activities was a negative ¥120,850,690.10, down 267.10% from ¥72,321,556.16 in 2021[32]. - The company reported a basic earnings per share of -¥0.26 in 2022, a decline of 388.89% from ¥0.09 in 2021[32]. - The company recognized investment losses of CNY 82.15 million due to policy impacts on its investment in a healthcare partnership[80]. - The company reported a total revenue of 134,970,809 RMB for the year 2022, with a net profit of 2,262,000 RMB, indicating a decrease of 115,200 RMB compared to the previous year[163]. Market Expansion and Product Development - The company plans to launch three new products in 2023, focusing on antibiotic and anti-infection therapies, aiming for a market share increase of 10%[24]. - Future guidance estimates revenue growth of 12% to 15% for 2023, driven by new product launches and market expansion efforts[24]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of RMB 300 million allocated for this purpose[24]. - The company is actively pursuing domestic and international product registrations to attract new customers and strengthen quality control[10]. - The company is focusing on expanding its market presence and enhancing its product offerings through new product development and technological advancements[166]. - The company aims to strengthen its lithium battery electrolyte additive segment by developing a series of products including VC, FEC, and BOB, and enhancing production capacity[140]. - The company has initiated a strategic acquisition of a smaller pharmaceutical firm, which is expected to enhance its product portfolio and increase annual revenue by 150 million yuan[176]. Research and Development - The company emphasizes the importance of R&D and plans to increase investment in product innovation and market research to ensure future growth[13]. - The company is investing RMB 200 million in R&D for new technologies, particularly in the field of β-lactam antibiotics[24]. - Research and development expenses increased by 30% in 2022, totaling 180 million yuan, reflecting the company's commitment to innovation[176]. - The company has established a new partnership with a leading research institution to enhance its drug development capabilities[176]. Operational Efficiency and Cost Management - The company aims to optimize production processes and improve automation to reduce raw material consumption and enhance production efficiency[10]. - The company has implemented a standardized procurement process to control raw material costs and ensure timely production, aligning procurement plans with sales forecasts[64]. - The company plans to implement comprehensive cost reduction and efficiency enhancement measures across various business modules in 2023[139]. - The company has optimized its production processes and is exploring energy utilization and circular economy strategies to further reduce costs[55]. Environmental and Compliance Commitment - The company is committed to environmental protection and has implemented measures to reduce pollution and comply with stricter regulations[12]. - The company emphasizes the importance of safety production management, aiming for a balance between safety and economic development[143]. - The company has established a comprehensive internal control system in compliance with relevant laws and regulations to enhance corporate governance and risk management[144]. - The company is committed to transparent information disclosure, ensuring all shareholders have equal access to information[156]. Financial Management and Governance - The company has a governance structure that includes a board of directors with 7 members, including 3 independent directors, ensuring compliance with legal requirements[151]. - The company has implemented a performance evaluation system for senior management, linking their performance directly to compensation[155]. - The total pre-tax compensation for the chairman and general manager, Bao Jianhua, is 132.02 million[178]. - The company has established a long-term mechanism for hidden danger investigation and rectification in safety management[143]. Challenges and Risks - The company experienced significant profit pressure due to rising raw material prices, public health events, and decreased product prices from newly launched projects, leading to a substantial decline in key financial metrics[8]. - The company acknowledges risks related to market competition, particularly in the pharmaceutical manufacturing sector, and is focused on developing a sustainable product portfolio[12]. - The company is aware of the risks associated with raw material price fluctuations and is taking steps to stabilize procurement costs[15]. - The company has faced uncertainty regarding its ability to continue as a going concern, as indicated by the audit report for the most recent year[32].

Financial Performance - The company's revenue for Q1 2023 was ¥397.92 million, a decrease of 1.10% compared to ¥402.33 million in the same period last year[5]. - The net profit attributable to shareholders was a loss of ¥30.15 million, representing a decline of 207.86% from a profit of ¥27.95 million in the previous year[5]. - The basic and diluted earnings per share were both -¥0.06, down 220.00% from ¥0.05 in the same quarter last year[5]. - The company's net profit for the period was -¥33.59 million, a decline of 244.28% compared to a profit of ¥23.28 million in the previous year, mainly due to a decrease in product prices and gross profit margins[9]. - Total operating revenue for Q1 2023 was CNY 397,918,173.64, a decrease of 1.03% compared to CNY 402,333,468.40 in the same period last year[27]. - Net profit for Q1 2023 was a loss of CNY 33,590,833.08, compared to a profit of CNY 23,281,932.07 in Q1 2022, indicating a significant decline in profitability[29]. - Total revenue from sales of goods and services received in Q1 2023 was CNY 124,519,192.17, a decrease from CNY 246,083,864.83 in Q1 2022[31]. Cash Flow and Assets - The net cash flow from operating activities was -¥94.83 million, a decrease of 93.69% compared to -¥48.96 million in the same period last year[5]. - Cash and cash equivalents at the end of Q1 2023 were CNY 689,922,521.41, down from CNY 978,027,566.82 at the beginning of the year, representing a decline of 29.48%[24]. - Total current assets decreased to CNY 1,953,998,677.02 from CNY 2,229,278,305.12, reflecting a reduction of 12.34%[24]. - Total liabilities decreased to CNY 2,207,864,324.57 from CNY 2,370,197,741.24, a decline of 6.86%[25]. - The company's total assets decreased to CNY 4,865,366,311.20 from CNY 5,059,834,182.46, a decline of 3.84%[25]. - Cash flow from operating activities showed a net outflow of CNY 94,831,724.81 in Q1 2023, worsening from a net outflow of CNY 48,959,708.08 in Q1 2022[32]. - Cash and cash equivalents at the end of Q1 2023 were CNY 619,312,659.18, down from CNY 1,218,580,837.61 at the end of Q1 2022, a decrease of approximately 49%[32]. Costs and Expenses - Total operating costs for Q1 2023 were CNY 431,474,684.77, an increase from CNY 372,752,389.58 in Q1 2022, representing a growth of approximately 15.8%[28]. - Research and development expenses increased to CNY 19,477,717.76 in Q1 2023 from CNY 16,774,533.75 in Q1 2022, reflecting a growth of about 10.1%[28]. - Financial expenses increased by 187.22% to ¥10.87 million due to higher interest expenses from increased borrowings[9]. - The company reported a significant decrease in other income, down 69.18% to ¥1.05 million, primarily due to reduced government subsidies received[9]. Strategic Focus and Development - The decline in performance was primarily due to high raw material prices and decreased product prices, which compressed profit margins[14]. - The company plans to focus on cost reduction and efficiency improvement across various business modules to enhance market competitiveness[16]. - In 2023, the company aims to strengthen its lithium battery electrolyte additive segment and expand its product line with VC, FEC, and BOB series products[17]. - The company is also developing new electronic chemicals and specialty materials to cultivate potential in the new materials sector[17]. - The company emphasizes safety production as a critical aspect of its operational strategy[19]. - The company emphasizes the importance of safety production management and compliance governance as key drivers for sustainable development[21]. - The company is committed to enhancing its safety culture and management systems to ensure a safe working environment[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,828[12]. - The company holds 11,355,900 shares in its repurchase account, accounting for 2.06% of the total share capital[13]. - A proposal for a simplified procedure to issue up to RMB 300 million in new shares, not exceeding 20% of the latest year's net assets, will be presented to the shareholders' meeting[18]. Audit Information - The company did not undergo an audit for the Q1 2023 report[33].

证券代码：300497 证券简称：富祥药业 公告编号：2023-044 江西富祥药业股份有限公司 关于举行2022年年度报告业绩网上说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）2022 年年度报告全文及其报告 摘要于 2023 年 4 月 26 日刊登于中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）。 为了更好地与广大投资者进行交流，使投资者能够进一步了解公司的生产经营情 况，公司定于2023年5月16日（星期二）15：00-17：00在全景网举办公司2022年年度 业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可登陆全景网 "投资者关系互动平台"（https://ir.p5w.net）参与本次年度业绩说明会。 欢迎广大投资者积极参与本次网上说明会。 （问题征集专题页面二维码） 特此公告。 江西富祥药业股份有限公司 董事会 2023 年 4 月 25 日 出席本次说明会的人员有：公司董事长兼总经理包建华先生、独立董事刘洪先生、 财务总监杨光 ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥股份 编号：20160628 | --- | --- | --- | |----------------|-------------------------|--------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 | 西南证券 周平 | | | 人员姓名 | 泰康资产 王晓锋 | | | | 融通基金 曹姗姗 | | | 时间 | 2016 年 6 月 28 | 日 10:00-12:00 | | 地点 | 公司本部 | | | 上市公司接待人 | | | | 员姓名 | 董事会秘书 黄晓东 | | | 投资者关系活动 | | 首先，董事会秘书介绍了公司的基本情况，以及未来的 | | 主要内容介绍 | 发展规划。 | | | | | 其次，是投资者互动环节： | | ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥股份 编号：20170116 | --- | --- | --- | --- | |----------------|---------------------------|--------------------------|--------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | | √ 现场参观 □其他 | | | | 参与单位名称及 | 中融基金管理有限公司 杜伟 | | | | 人员姓名 | 招商证券 李勇剑 | | | | | 方正证券 蒋一樊 | | | | | 平安证券 梁欢 | | | | | 中泰证券 池陈森 | | | | 时间 | 2017 年 1 月 16 | 日 11:00-15:30 | | | 地点 | 公司本部 | | | | 上市公司接待人 | | | | | 员姓名 | ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20200521 | --- | --- | --- | |-----------------------|------------------------------|------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 | | 长城国瑞证券 郑学军；长城国瑞证券黄文忠；长城国瑞证 | | 人员姓名 | 券 胡晨曦 | | | 时间 | 2020 年 5 月 21 日 | 9:30-11:30 | | 地点 | 公司本部 | | | | | | | 上市公司接待人 员姓名 | | 董事会秘书 黄晓东；证券事务代表 彭云 | | 投资者关系活动 | | 一、介绍公司基本情况： | | 主要内容介绍 | 基本情况： | | | | 公司成立于 | ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥药业 编号：20200514 | --- | --- | --- | |-------------------------|-------------------------|------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 □其他 | | | 参与单位名称及 人员姓名 | | 睿远基金 朱璘；睿远基金 汤国柱 | | | | | | 时间 | 2020 年 5 月 14 | 日 10:00-12:00 | | 地点 | 公司本部 | | | 上市公司接待人 员姓名 | | 董事长 包建华 ；董事会秘书 黄晓东；证券事务代表 彭云 | | 投资者关系活动 | | 一、介绍公司基本情况： | | 主要内容介绍 | | 基本情况：公司以特色抗菌原料药及其中间体的研发、 | | | | 生产和 ...

江西富祥药业股份有限公司 投资者关系活动记录表 证券代码：300497 证券简称：富祥股份 编号：20180117 | --- | --- | --- | |-----------------------|-------------------------|------------------------------------------------------| | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | 类别 | □ 新闻发布会 □路演活动 | | | | □ 现场参观 □其他 | | | 参与单位名称及 | 华鑫证券 杜永宏 | | | 人员姓名 | 华鑫证券 汤锋 | | | 时间 | 2018 年 1 月 17 | 日 14:30-17:00 | | | | | | 地点 | 公司本部 | | | 上市公司接待人 员姓名 | 董事会秘书 黄晓东 | | | 投资者关系活动 | | 首先，董事会秘书黄晓东介绍了公司的基本情况，以及 | | 主要内容介绍 | 未来的发展规划。 | | | | 公司基本情况： | 公司创建于 2002 ...

承诺 书 江西富祥药业股份有限公司: | --- | --- | |-----------|-----------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | 本人(公司)将对你公司进行调研(或采访等),根据有关规定作出如下承 | | 诺: | | | | (一)本人(公司)承诺在调研(或采访等)过程中不故意打探公司未公开 | | | 重大信息,未经公司许可,不与公司指定人员以外的人员进行沟通或问询; | | | (二)本人(公司)承诺不泄漏在调研(或采访等)过程中无意中获取的公 | | | 司未公开重大信息,不利用所获取的未公开重大信息买卖公司证券或建议他人买 | | | 卖公司证券; (三)本人(公司)承诺在投资价值分析报告、新闻稿等文件中不使用本次 | | | 调研（或采访等）获取的公司未公开重大信息,除非公司同时披露该信息; | | | (四)本人(公司)承诺基于本次调研(或 ...